uploads/2017/11/Established.png

How Bristol-Myers Squibb’s Established Products Performed in 3Q17

By

Updated

Baraclude revenue trends

In 3Q17, Bristol-Myers Squibb’s (BMY) Baraclude generated revenues of $264 million, a ~14% decline on a year-over-year (or YoY) basis and a 3% decline on a quarter-over-quarter basis. In 3Q17, in the US market and outside the US markets, Baraclude reported revenues of $14 million and $250 million, respectively, compared to $17 million and $289 million in 3Q16.

Baraclude reported revenues of $819 million during the first nine months of 2017 compared to $896 million in the corresponding period of 2016. Baraclude is used to treat the hepatitis B virus infection.

Article continues below advertisement

Sustiva franchise revenue trends

In 3Q17, the Sustiva franchise generated revenues of $183 million, a ~33% decline on a YoY basis and a 3% decline on a quarter-over-quarter basis. In 3Q17, in the US market and international markets, the Sustiva franchise generated revenues of $157 million and $26 million, respectively, compared to $234 million and $41 million in 3Q16.

The Sustiva franchise reported revenues of $555 million during the first nine months of 2017 compared to $819 million in the corresponding period of 2016.

Reyataz franchise revenue trends

In 3Q17, the Reyataz franchise generated revenues of $174 million, a ~27% decline on a YoY basis and a 7% decline on a quarter-over-quarter basis. In 3Q17, in the US market and international markets, Reyataz generated revenues of $85 million and $89 million, respectively, compared to $125 million and $113 million in 3Q16.

The Reyataz franchise reported revenues of $555 million during the first nine months of 2017 compared to $706 million in the corresponding period in 2016. Sustiva and Reyataz are used for the treatment of human immunodeficiency virus type 1 (or HIV -1) infection.

Article continues below advertisement

Hepatitis C franchise revenue trends

In 3Q17, Bristol-Myers Squibb’s Hepatitis C franchise generated revenues of $73 million, a ~81% decline on a YoY basis and a 35% decline on a quarter-over-quarter basis. In 3Q17, in the US market and international markets, the Hepatitis C franchise generated revenues of $24 million and $49 million, respectively, compared to $192 million and $187 million in 3Q16.

The Hepatitis C franchise reported revenues of $347 million during the first nine months of 2017 compared to $1.4 billion in the corresponding period of 2016.

Bristol-Myers Squibb’s hepatitis C franchise competes with Gilead Sciences’ (GILD) Harvoni, Epclusa, and Sovaldi, AbbVie’s (ABBV) Technivie, and Merck’s (MRK) Zepatier. In 3Q17, Harvoni, Epclusa, Sovaldi, and Zepatier reported revenues of $973 million, $882 million, $219 million, and $468 million, respectively.

The Vanguard Growth ETF (VUG) invests 0.93% of its total portfolio holdings in Bristol-Myers Squibb.

Advertisement

More From Market Realist